Poland· PL-100181530
Rimantin
A rimantadine product containing rimantadini hydrochloridum, registered in Poland by Genexo Sp. z o.o.. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rimantadine is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AC02 (rimantadine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Rimantadine · ATC J05AC02
2 / 19 countries
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Rimantadini hydrochloridum
- Manufacturer
- Genexo Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- J05AC02
- ATC class
- Rimantadine
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- August 30, 2026
Packs & prices · 2
- gtin05909990685349
- gtin05909990685356
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
11 interactions on record for rimantadine.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rimantadine · interactions on record
11 records
- 4 severe
- 6 moderate
- 1 minor
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rimantadine in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Bulgaria · Ремантадин Екофарм Груп Ад
- Lithuania · Rimantadinum Olpha
- Latvia · Remantadīns
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cdb2ce61-7175-4cde-a0d0-b92856bcec5a GET /v1/drugs/cdb2ce61-7175-4cde-a0d0-b92856bcec5a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "50 mg",
"packaging": "05909990685349 ¦ Rp ¦ 38478\n10 tabl.\n05909990685356 ¦ Rp ¦ 51163\n20 tabl.",
"substance": "Rimantadini hydrochloridum 50 mg",
"common_name": "Rimantadini hydrochloridum",
"pl_product_id": "100181530",
"pozwolenie_nr": "15582",
"auth_procedure": "NAR",
"authorisation_validity": "2023-09-01"
}See everything about rimantadine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.